Oxfendazole

Catalog No.S1830 Synonyms: RS-8858

For research use only.

Oxfendazole (RS-8858) is a broad spectrum benzimidazole anthelmintic.

Oxfendazole Chemical Structure

CAS No. 53716-50-0

Selleck's Oxfendazole has been cited by 1 Publication

Purity & Quality Control

Choose Selective Parasite Inhibitors

Biological Activity

Description Oxfendazole (RS-8858) is a broad spectrum benzimidazole anthelmintic.
In vivo Oxfendazole (OX) induces not only mRNA expression of phase I enzymes Cyp1a1, Cyp1a2, but also Nrf2-regulated phase II enzymes such as Gpx2, Nqo1, Yc2, Akr7a3 and Gstm1 in rats, presumably due to an adaptive response against OX-induced oxidative stress. Oxfendazole enhances oxidative DNA damage (as assessed by 8-hydroxydeoxyguanosine; 8-OHdG) and lipid peroxidation (as assessed by thiobarbituric acid-reactive substances; TBARS) in rats. [1] Oxfendazole administered at the therapeutic dose (4.5 mg/kg) and at the highest dose (22.5 mg/kg) increase 1.54- and 2.36-fold the total liver microsomal cytochrome P450 and more particularly the isoenzyme P450IA2 (95% and 184% increases) in rabbit liver. [2] Oxfendazole MRL induces a mutagenic effect in all tested cell types. Oxfendazole exhibits embryotoxicity including teratogenicity. Oxfendazole induces a disturbance in the different biochemical contents of all tested tissues in mice. [3] Oxfendazole increases the incidence and multiplicity of altered foci (4.0- and 3.6-fold, respectively) and hepatocellular adenomas (HCAs) (3.0- and 5.5-fold, respectively). Oxfendazole treatment induces 5.2- and 5.6-fold increases in the number of proliferating cell nuclear antigen (PCNA)-positive cells and single-stranded DNA (ssDNA)-positive cells in HCAs compared with the surrounding tissue, respectively. [4] Oxfendazole and its sulphone metabolite attain a significantly higher plasma concentration and remain much longer in plasma compared with fenbendazole (FBZ) and albendazole (ABZ) and their respective metabolites in dogs. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 10 mg/mL
(31.71 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 315.35
Formula

C15H13N3O3S

CAS No. 53716-50-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04920292 Not yet recruiting Drug: Oxfendazole|Drug: Placebo Filariasis Swiss Tropical & Public Health Institute|Ifakara Health Institute|Drugs for Neglected Diseases December 1 2021 Phase 1
NCT02636803 Withdrawn Drug: oxfendazole|Drug: albendazole Helminthiasis Johns Hopkins Bloomberg School of Public Health|Universidad Peruana Cayetano Heredia November 2019 Phase 2
NCT03035760 Completed Drug: Oxfendazole Helminthic Infection National Institute of Allergy and Infectious Diseases (NIAID) May 12 2017 Phase 1
NCT02234570 Completed Drug: Oxfendazole|Other: Placebo Neurocysticercosis National Institute of Allergy and Infectious Diseases (NIAID) November 17 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Oxfendazole | Oxfendazole ic50 | Oxfendazole price | Oxfendazole cost | Oxfendazole solubility dmso | Oxfendazole purchase | Oxfendazole manufacturer | Oxfendazole research buy | Oxfendazole order | Oxfendazole mouse | Oxfendazole chemical structure | Oxfendazole mw | Oxfendazole molecular weight | Oxfendazole datasheet | Oxfendazole supplier | Oxfendazole in vitro | Oxfendazole cell line | Oxfendazole concentration | Oxfendazole nmr